Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus neoadjuvant chemotherapy in advanced ovarian cancer
NCT04815408Phase 2Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Apr 2021
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in ovarian cancer, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04815408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04815408.